Roche Tecentriq immunotherapy cocktail wins USFDA approval for treating lung cancer

The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene's Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations, Roche said on Wednesday.

New Delhi: Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.

Also Read: Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene's Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations, Roche said on Wednesday.

Read Also: Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020